ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer: Part 1

Use of first-line (1L) OPDIVO® (nivolumab) in combination with low-dose YERVOY® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%

The Lynx Group: 2021 Ask The Expert MDietrich.pdf
Please Click the Issue to Download


This resource provides insights and guidance by a thought leader into frequently asked questions on the open-label, phase 3, Checkmate 227 study evaluating the use of 1L nivolumab in combination with low-dose ipilimumab in patients with metastatic NSCLC and PD-L1 ≥1%. It was recently updated to include 4-year extended follow-up data for the Checkmate 227 study, with a median follow-up of 54.8 months, presented by researchers at the American Society of Clinical Oncology 2021 annual meeting.

Download to Continue Reading